637 results
Showing 1–20 · 0.19 seconds · RSS
Multiple Sclerosis Journal - Experimental, Translational and Clinical
Scopus
ISSN 2055-2173 · SAGE Publishing · 637 articles in the index
-
Journal Article
Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): A mixed-methods, multi-centre feasibility randomised controlled trial
Background Cognitive difficulties are common in people with multiple sclerosis (pwMS), yet access to neuropsychological rehabilitation is often limited or only provided to those with more severe impairments. The NEuRoMS intervention provides brief, tailored neuropsychological rehabilitation for…
-
Journal Article
Epidemiology of multiple sclerosis in a healthcare area of the Basque Country, Northern Spain: A population-based study (2009–2023)
Background Multiple sclerosis (MS) prevalence has increased across Europe, yet contemporary population-based data from southern Europe remain scarce. Objectives In this retrospective population-based cohort study conducted in a healthcare area of the Basque Country (Barrualde-Galdakao Integrated…
-
Journal Article
Prevalence and incidence of multiple sclerosis in Kosovo: Data from Kosovan national multiple sclerosis registry
Background Many studies report different prevalence and incidence estimates for multiple sclerosis (MS). Epidemiological data from Southeast Europe remain scarce. Objectives This study aimed to estimate the prevalence, incidence, and demographic characteristics of MS in the Republic of Kosovo using…
-
Journal Article
The constrained brain in multiple sclerosis: Cognitive impairment is related to network-specific coupling of structural and functional connectivity
Background Cognitive impairment in multiple sclerosis (MS) is related to abnormal structural and functional brain network changes. As both modalities have mostly been studied separately, structure connectivity-function coupling (SC-FC) may elucidate how function is constrained by structure…
-
Journal Article
Long-term outcomes of autologous haematopoietic stem cell transplantation in multiple sclerosis: A retrospective single-centre experience
Background Autologous haematopoietic stem cell transplantation (AHSCT) is a potential therapeutic strategy for patients with relapsing multiple sclerosis (pwRMS) unresponsive to disease-modifying therapies (DMTs), though its optimal position in the treatment algorithm remains undefined. Objective…
-
Journal Article
Desired clinic characteristics and unmet support needs for adults with multiple sclerosis: A cross-sectional survey
Background Patients with multiple sclerosis (MS) have individual needs, preferences, and barriers to how they receive care; providers require an understanding of these to facilitate comprehensive clinical care. Objective To determine MS clinic characteristics currently valued by or desired by…
-
Journal Article
Workplace difficulties in early-stage relapsing-remitting multiple sclerosis with low physical disability
This study evaluated perceived workplace difficulties in 128 individuals with early-stage relapsing-remitting multiple sclerosis and low physical disability. Significant workplace challenges were reported by 40.6% of participants. External barriers, including workplace inflexibility and…
-
Journal Article
Absence of significant hematologic abnormalities in breastfed infants of mothers with multiple sclerosis treated with anti-CD20 therapies
Objectives To assess hematologic abnormalities in breastfed infants of mothers with multiple sclerosis (MS) receiving anti-CD20 therapies. Methods Breastfed infants with maternal anti-CD20 use were identified. Infant blood draws examined B-cell (CD19) and hematological counts. Results Nine of 10…
-
Journal Article
Acute effects of high-dose corticosteroids on serum biomarker profiles in primary CNS demyelinating disease: A pilot study
Background Acute inflammatory relapses in primary CNS demyelinating diseases, including relapsing multiple sclerosis (RMS), MOG-antibody-associated disease (MOGAD), and neuromyelitis optica spectrum disorder (NMOSD), drive hospitalization, disability, and socioeconomic burden. Blood-based…
-
Journal Article
Real-world adherence to and persistence with ofatumumab, infusion, oral, and other self-injectable disease-modifying therapies in patients with multiple sclerosis
Background Treatment schedule complexity and route of administration may influence patient adherence and persistence. Limited real-world evidence exists comparing these outcomes across treatments for multiple sclerosis (MS). Objective To examine 18- and 24-month adherence/persistence of ofatumumab…
-
Journal Article
Sex-dependent bioactive lipid mediator profiles in multiple sclerosis
Background Pathophysiological drivers of sex differences in multiple sclerosis (MS) remain unclear. Potential candidates include bioactive lipid mediators (LMs), which are pivotal regulators of neuro-inflammatory responses. Objective To investigate sex-dependent LM differences in MS. Methods Plasma…
-
Journal Article
Walking fatigability indices correspond with perception of changes in gait speed and quality during an instrumented 6-minute walking test in people with multiple sclerosis
Background People with MS (pwMS) present changes in gait speed and quality during a 6-min walking test (6MWT). It is unknown whether these changes are clinically meaningful. Objective To examine the relationships between pwMS-perceived changes in gait speed and quality with walking fatigability…
-
Journal Article
Real world observation of fatigue in multiple sclerosis comparing self-guided online cognitive behavioral therapy versus psychoeducation
Background Fatigue is a common symptom in people with multiple sclerosis (pwMS) with severe implications. A self-guided, internet-based intervention to reduce fatigue in MS, based on cognitive behavioral therapy (CBT), is approved as a digital health application (DiGA) in the German healthcare…
-
Journal Article
Effect of ocrelizumab on rates of retinal atrophy in relapsing multiple sclerosis
Background Ganglion cell + inner plexiform layer (GCIPL) atrophy reflects global neurodegeneration and disability in multiple sclerosis (MS). The effect of ocrelizumab, an anti-CD20 monoclonal antibody and highly-effective disease modifying therapy (DMT), on rates of GCIPL atrophy in people with MS…
-
Journal Article
Assessing the feasibility, theoretical interest, and observed behaviors of adding genetic data to a patient-reported multiple sclerosis registry
Background and Objectives We aimed to assess the feasibility and acceptability of self-collected saliva for genetics from participants of a registry and determine whether responses to hypothetical questions regarding sharing of genetic information reflected observed behaviors. Methods We conducted…
-
Journal Article
Patterns and predictors of transition between multiple sclerosis phenotypes: A longitudinal analysis
Background Multiple sclerosis (MS) phenotype transitions are challenging to characterize. Our understanding of their predictors is also limited. Objective To investigate the transition between relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) within the Comprehensive Longitudinal…
-
Journal Article
Establishing humoral immunity to rabies in a person with multiple sclerosis through booster vaccination: A case report
It is known that certain disease-modifying therapies for multiple sclerosis impair humoral immunity; however, data on the effect of therapies on humoral immunity with human diploid cell rabies vaccine is limited. Here we present a case of a 31-year-old male with multiple sclerosis on ofatumumab who…
-
Journal Article
Early switching to ofatumumab avoids a rebound effect after natalizumab cessation in multiple sclerosis patients
Background A risk of disease reactivation has been clearly identified after natalizumab cessation in patients with multiple sclerosis (MS). Several studies have demonstrated a low risk of reactivation or rebound in patients switching to anti-CD20, but limited data are available concerning…
-
Journal Article
Predictors of high- versus low-intensity first-line multiple sclerosis treatments
Background Disease-modifying therapies (DMTs) for multiple sclerosis (MS) can be either high- or low-intensity. This study aims to examine predictors associated with high-intensity MS treatment strategies using commercial claims data. Methods We used Merative MarketScan commercial and Medicare…
-
Journal Article
Continuous ofatumumab treatment until the early third trimester in multiple sclerosis with preserved neonatal immunity
Evidence regarding neonatal immune outcomes following late-gestation exposure to ofatumumab remains limited. We report a 35-year-old woman with relapsing multiple sclerosis who continued ofatumumab until 28 weeks of gestation following individualized shared decision-making based on informed patient…